Mersana Therapeutics

Search
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
  • Technology Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Publications
  • Investors & Media
    • Overview
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Press Releases
    • Events & Presentations
    • Annual Meeting
    • Corporate Governance
    • Investor FAQs
    • Contact Us
  • Careers
    • Culture
    • Benefits
    • Open Positions
  • Contact
Immunosynthen, Publications, XMT-2056

XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab

April, 2022

Dolasynthen, Publications, XMT-1660

Anti-tumor effect of XMT-1660, a B7-H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer

April, 2022

Immunosynthen, Program, Publications

Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potential anti-tumor activity by delivering STING agonist specifically to tumor cells and FcγRI-expressing subset of myeloid cells

April, 2022

Dolaflexin, Platform, Program, Publications, UpRi (XMT-1536)

UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of Upifitamab Rilsodotin (XMT-1536; UpRi), an NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer

March, 2022

Dolaflexin, Platform, Program, Publications, UpRi (XMT-1536)

Updated Results From the Phase 1b Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer

March, 2022

Dolaflexin, Platform, Program, Publications, UpRi (XMT-1536)

UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer

March, 2022

Dolaflexin, Platform, Program, Publications, UpRi (XMT-1536)

Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): Updated Analysis of a Phase 1b Expansion Study in Ovarian Cancer

March, 2022

Immunosynthen, Publications

STING-Agonist ADCs Targeting Tumor-Associated Antigens Coordinate Immune-Mediated Killing of Antigen-Negative Cancer Cells

Dolasynthen, Publications

Site Specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

October, 2021

Immunosynthen, Publications, XMT-2056

XMT-2056: Tumor-targeted Innate Immune Activation via a STING-agonist Antibody Drug Conjugate

October, 2021

© 2022 Mersana Therapeutics, All Rights Reserved. Privacy Policy | Terms of Use
linkedin icon twitter icon facebook icon instagram icon
logo
  • About
    • Mission & Vision
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Overview
    • Upifitamab Rilsodotin
  • Technology Platforms
    • About ADCs
    • DolaLock Technology
    • Dolaflexin
    • Dolasynthen
    • Immunosynthen
  • Publications
  • Investors & Media
    • Overview
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Press Releases
    • Events & Presentations
    • Annual Meeting
    • Corporate Governance
    • Investor FAQs
    • Contact Us
  • Careers
    • Culture
    • Benefits
    • Open Positions
  • Contact